The goal of the Award is to promote and reward two excellent innovative nanomedicine-based solutions that could help physicians change the way diseases are treated and diagnosed, bringing significant benefits to patients.
The Award is open to companies as well as academic and private researchers across the globe.
Nominated projects should be totally new diagnostic and therapeutic approaches that address unmet medical needs with nanomedicine, and have an explicit and defined potential market.
Nanomedicine proposals will be evaluated in two categories:
Best early clinical stage project Award
Best product or deal Award
Applications will be reviewed and assessed by a panel of highly-qualified pharma industry experts with experience in R&D and business roles: Patrick Boisseau, Business Development Nanomedicine at CEA Leti and President of the ETPN; Patrick Tricoli, VP Corporate Development and CEO Nanobiotix Corp.; Jeff Hrkach, formerly Chief Technology Officer of BIND Therapeutics, Inc. and member of the Nanomedicines Alliance and Henry Havel, formerly Senior Research Fellow at Eli Lilly and Chairman of the Nanomedicines Alliance. For the first time in its history, ETPN gets together with the US-based Nanomedicines Alliance for a meaningful initiative.
The Award is supported by the EBD Group, the leading partnering firm for the global life science industry, the Nanomedicines Alliance, the US-based consortium dedicated to promoting and facilitating the scientific advancement, regulatory approval, and public appreciation of nanotechnology-based medicines and Nanobiotix, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Award ceremony will take place during BIO-Europe 2015 in Munich, Germany, on November the 3rd, 2015.
Winners will benefit from a full registration (including partnering) for BIO-Europe 2015 and a 10 minutes project presentation during the Conference. The winning projects will also be granted with a presentation during the ETPN General Assembly 2016, along with 1 year’s free ETPN membership and a consulting action by the experts from the Translation Advisory Board (TAB). The winners will gain visibility to EU decision makers from pharma industry, academia, finance and media.
Entries for nominations for the Award will be open until September 15, 2015.